Applications in Biopesticide Crop Protection and Animal Health
VANCOUVER, BC, Nov. 29, 2022 /PRNewswire/ – Renaissance BioScience Corp., a leader in bioengineering for the global agriculture and food industries, is pleased to announce that it has retained the services of S. Brad Griffith to assist Renaissance in commercializing its RNA production and oral delivery platform technology applications for agricultural crop protection, non-agriculture biocontrol and animal health.
Mr. Griffith has more than 30 years’ experience in the agriculture industry and life sciences, much of it at a senior executive level, including leading the global commercial BioAg Alliance, a joint venture of Monsanto and Novozymes representing the largest microbials business in the world at that time. He was most recently Chief Commercial Officer at Compass Minerals, an Overland Park, KS-based NYSE public company.
Maurice Boucher, Renaissance’s Executive Chair, commented: “Brad’s industry knowledge, strategic vision, and operational implementation capabilities are a perfect fit to maximize the extensive global commercial opportunities for valuable product creation in agricultural crop protection, animal health and biocontrol that the Renaissance RNA platform technology has application for. Renaissance’s technology addresses the need for environmentally friendly agriculture technologies that are effective and affordable. With the help of experienced senior industry executives like Brad Griffith, we can make major contributions to the future of sustainable agriculture.”
Mr. Griffith commented: “I am impressed by the innovation capabilities and IP of Renaissance BioScience and their potential to develop next-generation technologies that can help producers maximize economic returns more sustainably. I am excited to work with the Renaissance team to bring their technologies to industry. They are very open to partnerships and co-creation.”
About Renaissance BioScience Corp.
Based in Vancouver, Canada, Renaissance is a leading bioengineering company whose platform technologies are used to develop innovative, market-ready, functional microorganisms that provide cost-effective solutions to a broad range of environmental, health and industrial efficiency problems. Renaissance technologies create products for multiple end-use industries, including agriculture, food & beverage, animal and human health and energy. www.renaissancebioscience.com.
View original content:https://www.prnewswire.com/news-releases/renaissance-bioscience-corp-adds-agribusiness-industry-senior-executive-expertise-to-accelerate-the-commercialization-of-its-rna-production-and-oral-delivery-platform-technology-301688435.html
SOURCE Renaissance BioScience Corp.
Medical Properties (MPW) witnessed a jump in share price last session on above-average trading volume.
Big dividend yields can be alluring. Unfortunately, many higher-yielding dividends are at high risk of getting cut if market conditions deteriorate. Because of that, yield-focused investors should avoid that stock and instead consider buying Energy Transfer (NYSE: ET) or Verizon (NYSE: VZ).
Canaccord Genuity Managing Director George Gianarikas joins Yahoo Finance Live to discuss the market’s reaction to Tesla stock, how investors are dealing with the stock following uncertainty, uncertainty around EV delivery, a recession, growth, and the outlook for sustained leadership within the EV space.
The average brokerage recommendation (ABR) for Plug Power (PLUG) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Berkshire Hathaway should generate more than $6 billion in dividend income over the next 12 months. Nearly half of it will come from three stocks.
Due to economic and geopolitical headwinds, financial markets have been exceptionally volatile in 2022. Goldman Sachs (NYSE: GS) recently noted that this year would likely be the sixth-most-volatile year dating back to the Great Depression. Shares of the hospital real estate investment trust (REIT) Medical Properties Trust (NYSE: MPW) have plunged 53% so far this year.
Tesla has found a steadfast bull.
The S&P 500 had its worst first half since 1970, the Nasdaq Composite suffered its sharpest decline in more than a decade, and both indexes have fallen into a bear market. For instance, cybersecurity leaders CrowdStrike Holdings (NASDAQ: CRWD) and Zscaler (NASDAQ: ZS) have seen their share prices fall 65% and 70%, respectively, but both companies have continued to report monster financial results. CrowdStrike provides 23 software modules that address several cybersecurity verticals, from endpoint security to threat intelligence.
This holiday season hasn’t exactly been filled with cheer for investors: Companies have been battling inflation and market volatility—and a recession seems to be looming ahead. Here’s what you need to know about trading hours ahead of Christmas. Is the Stock Market Closed Today?
Not long ago considered a trailblazing investing guru, sentiment has entirely shifted around Cathie Wood over the past year and a half. Her ARK Invest fund’s ARK Innovation ETF is loaded with growth-oriented pandemic-era winners but as anyone following the stock market’s trajectory will know, the tables have turned on stocks of that ilk. And the result is that the ARKK ETF is now down by a huge 65% in 2022. Does that mean Wood is ready to desert her strategy of backing innovative yet risky and o
Devon Energy (DVN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Investors just woke up to the fact that Carnival's fourth-quarter earnings report actually wasn't that great.
Let's say you have $250 to spare after paying off your bills, clearing your high-interest debt, and saving enough for a rainy day: You can consider buying one share of Palo Alto Networks (NASDAQ: PANW) and almost two shares of Sea Limited (NYSE: SE) right now. Shares of the cybersecurity specialist slipped nearly 20% as of this writing, and that has made the stock cheaper than before. More specifically, Palo Alto stock is now trading at less than 8 times sales, which is well below the price-to-sales ratio of nearly 12 that it was commanding last year.
The Dow Jones Industrial Average dropped Friday on key inflation data. Tesla stock hit a new low amid Elon Musk's comments on not selling shares.
While the S&P 500 and Dow Jones Industrial Average are both sliding lower today, shares of Lithium Americas (NYSE: LAC) are outpacing the downward slide in the market writ large. Addressing the company's recent deal with Arena Minerals, an analyst from B. Riley seems to be unenthusiastic about the transaction, electing to keep the same price target and rating on the stock that he had prior to the announcement. As of 3:32 p.m. EST, shares of Lithium Americas are down 3.8%, recovering slightly from their earlier slide of 5.7%.
After three winning sessions in a row, the stock market fell on Thursday when the weekly jobless claims came in below the expectations. That data point indicated continued tightness in the labor market, but the Federal Reserve has been hoping to see signs of a moderate increase in unemployment, to indicate that the anti-inflationary rate increases are taking hold. Barring that evidence, the Fed is likely to continue raising rates and tightening monetary policy, increasing the risk of recession.
Yahoo Finance Live anchors discuss the decline in stock for Nutanix amid reports that Hewlett Packard Enterprise Co. has ended acquisition talks.
Tesla investors already lost nearly $700 billion on the stock this year. How much more can this S&P 500 stock drop?
The e-commerce giant is having one of its worst years in the stock market since the bursting of the internet bubble in 2000.
This week was going down as one to remember for Madrigal Pharmaceuticals (NASDAQ: MDGL). According to data compiled by S&P Global Market Intelligence, the biotech's shares were an eye-watering 350% higher week to date, as of Thursday's market close. Biotechs tend to pop like that when they report excellent clinical-trial results; such was the case with Madrigal.
Renaissance BioScience Corp adds AgriBusiness Industry Senior Executive Expertise to Accelerate the Commercialization of its RNA Production and Oral Delivery Platform Technology – Yahoo Finance
